Eli Lilly"s experimental cholesterol pill, muvalaplin, has shown promising results in a mid-stage trial, significantly reducing levels of lipoprotein(a), a genetic risk factor for heart disease. The highest dose decreased Lp(a) by 70% compared to placebo, with a favorable safety profile. Analysts suggest the drug could become a blockbuster if it proves effective in preventing cardiovascular events in future trials.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
